

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 338 295 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
27.08.2003 Bulletin 2003/35

(51) Int Cl.7: **A61M 5/172, A61M 5/145**

(21) Application number: **03251117.2**

(22) Date of filing: **25.02.2003**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT SE SI SK TR**
Designated Extension States:
AL LT LV MK RO

(30) Priority: **26.02.2002 US 360401 P**

(71) Applicant: **Lifescan, Inc.**
Milpitas, California 95035-6312 (US)

(72) Inventors:
• **Bylund, Adam David**
Fremont, California 94539 (US)
• **Durban, William Jefferey**
Pleasanton, California 94566 (US)

- **Wardle, Michael D.**
San Jose, California 95138 (US)
- **Long, Karen M.**
San Jose, California 95125 (US)
- **McClusky, Joseph**
Sharon, Massachusetts 02067 (US)
- **Kraft, Ulrich**
65719 Hofheim (DE)
- **Ebner, Manfred**
61440 Oberursel (DE)
- **Steine, Matthias**
Inverness IV2 3QG (GB)

(74) Representative: **Mercer, Christopher Paul et al**
Carpmaels & Ransford
43, Bloomsbury Square
London WC1A 2RA (GB)

(54) **Systems for remotely controlling medication infusion and analyte monitoring**

(57) Devices, systems and methods are provided for remotely controlling medication delivery to a patient by means of a medication infusion pump, such as a subcutaneous infusion pump, and for remotely controlling the monitoring of one or more physiological fluid analytes such as by a percutaneous measurement device. The systems of the present invention include a medication infusion pump and a hand-held "fob" for the remote control of the infusion pump and/or measurement device. In addition to remotely controlling the insulin pump and the measurement device, the fob provides for the

consolidation of blood chemistry data and insulin delivery data over a period of time and maintains such consolidated data for immediate and later retrieval by the user or a physician. The methods of the present invention allow a user to customize and optimize an insulin bolus delivery protocol, i.e., bolus volume and delivery duration, by factoring in or compensating for the user's current or substantially current blood chemistry evaluation and/or the user's anticipated and/or actual carbohydrate intake.

